A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer

Abstract p95HER2 is commonly expressed in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and is generated primarily from shedding of the extracellular domain of HER2. p95HER2 is oncogenic, driving aggressive tumor growth, and conferring drug resistance. Targeting p95HER2...

Descripció completa

Dades bibliogràfiques

Autors principals:	Lu Yang, Arup Bhattacharya, Yun Li, Darrell Peterson, Yuesheng Zhang
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2026-04-01
Col·lecció:	Scientific Reports
Matèries:	HER2 HER2-positive breast cancer HER2 inhibitors p95HER2 Resistance to HER2 inhibitors
Accés en línia:	https://doi.org/10.1038/s41598-026-47444-3
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!